Nevertheless, current clinical trials have demonstrated that VEGFR-1, as a fundamental mediator of both physiologic and developmental angiogenesis may direct to the aggressive actions of HCC cells (Yi et al., 2011). This evidence concerns the gene FLT1 and hepatocellular carcinoma.